Analyst estimates indicate an optimistic outlook for financial technology stocks, with 86 of 99 companies examined in an S&P Global Market Intelligence analysis trading below their mean one-year price targets as of Sept. 12. Of those companies, nine had implied upsides of at least 50%.
Evolent Health led the pack with a 143.2% implied upside, or the amount a stock needs to rise to hit analysts' average price target. Although the company's stock has struggled over the last year, dropping 73.2%, all but one of the 14 analysts covering Evolent had buy recommendations on it.
Ebix Inc. traded at the second-largest discount as of Sept. 12, with an upside to price target of 104.9%. Two of the three analysts covering Ebix had buy recommendations.
On the other end of the spectrum, MoneyGram International Inc. was trading 29.8% above its mean one-year price target, the largest premium among companies in the analysis. Only two of the four analysts covering the stock considered it a buy.
Diebold Nixdorf Inc. had overshot analyst price targets by 7.0% as of Sept. 12, thanks to a strong 177.1% return over the preceding 12 months.
In this analysis, S&P Global Market Intelligence examined major exchange-traded financial technology companies with at least three analyst recommendations and share prices above $5 as of Sept. 12.

